Metraipolis › archive › dc_8abb118de13f
Targeting NAT10 with Remodelin in cancer drug resistance: mechanisms, preclinical evidence, and combination strategies — Europe PMC PMID:42445245
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42445245
- DOI
- 10.3389/fphar.2026.1853392
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T07:24:55.536Z
- SHA-256 of the archived text
5385dcd038581fefab6bf292fa1d5a91a2245b9fc854add02fc655d35273b757- Stable URL of this page
https://metraipolis.com/documento/dc_8abb118de13f
How to cite
Targeting NAT10 with Remodelin in cancer drug resistance: mechanisms, preclinical evidence, and combination strategies — Europe PMC PMID:42445245 — Europe PMC (en), https://europepmc.org/article/MED/42445245 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8abb118de13f (Metraipolis archive dc_8abb118de13f, sha256 5385dcd038581fefab6bf292fa1d5a91a2245b9fc854add02fc655d35273b757)
BibTeX
@misc{dc8abb118de13f,
title = {Targeting NAT10 with Remodelin in cancer drug resistance: mechanisms, preclinical evidence, and combination strategies — Europe PMC PMID:42445245},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42445245},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8abb118de13f; sha256 5385dcd038581fefab6bf292fa1d5a91a2245b9fc854add02fc655d35273b757},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42445245. Agents can read the archived copy with the MCP tool read_document.